Gilead Sciences (GILD) has agreed to pay $202 million to settle claims that it violated US anti-kickback laws through its HIV drug speaker programs, according to a Tuesday statement by New York Attorney General Letitia James.

New York Attorney General Letitia James, leading a coalition of 48 other states, said $49 million will go to Medicaid programs nationwide.

The rest of the funds will reimburse federal health programs, including Medicare, impacted by the alleged misconduct, according to the statement.

Investigators said that from 2011 to 2017, Gilead paid healthcare providers to promote its HIV drugs, which led to false claims to federal programs, as per the statement.

Shares of the company were down about 2.6% in recent trading.

Price: 109.20, Change: -2.89, Percent Change: -2.58